Hosted on MSN20d
For people with nasal polyps, new asthma drug may offer hope
The trial marks the first time the drug has been tested for treating nasal conditions. Nasal polyps are thought to affect around 5% of people, and around 20% of patients with asthma. A total of ...
Physician's Weekly9h
Beyond Nasal Symptoms: How CRSwNP Impacts Mental Health
Recent studies examine the burden of CRSwNP, looking at quality of life in patients and caregivers and assessing how CRSwNP ...
Healio6d
Chronic rhinosinusitis with nasal polyps improves with tezepelumab
Patients with chronic rhinosinusitis with nasal polyps saw improvements across all endpoints with tezepelumab, according to ...
Infectious Disease Advisor4h
Silent Rhinovirus Infection Prevalent in Nasal Tissues
Silent rhinovirus (RV) infection is prevalent in nasal tissues and is associated with distinct immune responses in those with and without chronic rhinosinusitis with nasal polyps (CRSwNP). These were ...
Healthline7d
Eosinophilic Asthma
Eosinophilic asthma is a severe form of asthma caused ... Certain physical symptoms, such as nasal polyps, are consistent with the suspected diagnosis. The combination of the blood test and ...
Healio3d
Asthma Clinical Case Review
Roshni Naik, MD, allergist at Mount Sinai Health System, discusses the history of present illness for a case of severe asthma with nasal polyps: "Patient is a 45 year-old male with a past medical ...
Verywell Health on MSN3d
Is Vasomotor Rhinitis Causing Your Runny Nose?
Vasomotor rhinitis is a cause of runny nose and congestion not related to allergies or an infection. Learn about the symptoms ...
Clinical Advisor14d
FDA to Review Depemokimab for Asthma With Eosinophilic Phenotype, CRSwNP
The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...
Medical Xpress12d
Monoclonal antibody significantly reduces nasal polyps and need for surgery in Phase 3 clinical trial
Asthma exacerbations were also lower with tezepelumab (0.5%) compared to placebo (5.9%). At week 52, patients receiving tezepelumab showed a mean reduction in total nasal-polyp score of -2.07 ...
Pharm Exec21d
FDA Accepts Biologics License Application for GSK’s Depemokimab for Asthma with Type 2 Inflammation and CRSwNP
In the SWIFT and ANCHOR trials, depemokimab demonstrated statistically significant reductions in nasal polyp size, obstruction, and asthma exacerbations compared to placebo. The FDA has accepted GSK’s ...
Nasal Polyps Treatment Market Set To Surge To $4.24 Billion By 2030 At A 5.6% CAGR
Nasal Polyps Treatment Market Research Report The global nasal polyps treatment market is expected to reach around $4,243.9 million by 2030 ...
Medscape14d
Tezepelumab Eases Chronic Rhinosinusitis With Nasal Polyps
The asthma medication reduces congestion in patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps in a ...